Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
Description
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.